- Home
- TSHA vs STGW Comparison
TSHA vs STGW Comparison
Compare TSHA & STGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- STGW
- Stock Information
- Founded
- TSHA 2019
- STGW 1980
- Country
- TSHA United States
- STGW United States
- Employees
- TSHA N/A
- STGW N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- STGW
- Sector
- TSHA Health Care
- STGW
- Exchange
- TSHA Nasdaq
- STGW Nasdaq
- Market Cap
- TSHA 1.4B
- STGW 1.4B
- IPO Year
- TSHA 2020
- STGW N/A
- Fundamental
- Price
- TSHA $3.84
- STGW $4.85
- Analyst Decision
- TSHA Strong Buy
- STGW Buy
- Analyst Count
- TSHA 9
- STGW 5
- Target Price
- TSHA $10.22
- STGW $8.15
- AVG Volume (30 Days)
- TSHA 4.1M
- STGW 4.8M
- Earning Date
- TSHA 11-04-2025
- STGW 11-06-2025
- Dividend Yield
- TSHA N/A
- STGW N/A
- EPS Growth
- TSHA N/A
- STGW 1954.71
- EPS
- TSHA N/A
- STGW 0.06
- Revenue
- TSHA $6,310,000.00
- STGW $2,890,264,000.00
- Revenue This Year
- TSHA N/A
- STGW $4.18
- Revenue Next Year
- TSHA N/A
- STGW $9.16
- P/E Ratio
- TSHA N/A
- STGW $84.60
- Revenue Growth
- TSHA N/A
- STGW 6.75
- 52 Week Low
- TSHA $1.05
- STGW $4.03
- 52 Week High
- TSHA $5.51
- STGW $8.18
- Technical
- Relative Strength Index (RSI)
- TSHA 37.78
- STGW 45.56
- Support Level
- TSHA $3.89
- STGW $4.63
- Resistance Level
- TSHA $4.55
- STGW $6.88
- Average True Range (ATR)
- TSHA 0.39
- STGW 0.32
- MACD
- TSHA -0.19
- STGW 0.02
- Stochastic Oscillator
- TSHA 8.99
- STGW 9.78
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.